By targeting the tumor microenvironment to stimulate antitumor immunity, immunotherapies
have revolutionized cancer treatment. However, many patients do not respond initially or …

Mounting evidence has revealed that the therapeutic efficacy of immunotherapies is
restricted to a small portion of cancer patients. A deeper understanding of how metabolic …

Simple Summary In a tumor context, antitumor immune cells mediate an inflammatory
response after activating a metabolic switch to kill cancer cells. However, tumors develop …

Currently, a marked number of clinical trials on cancer treatment have revealed the success
of immunomodulatory therapies based on immune checkpoint inhibitors that activate tumor …

The growing field of immune metabolism has revealed promising indications for metabolic
targets to modulate anti-cancer immunity. Combination therapies involving metabolic …

Immunometabolism is an emerging discipline in cancer immunotherapy. Tumor tissues are
heterogeneous and influenced by metabolic reprogramming of the tumor immune …

The development of immune checkpoint blockade (ICB) therapies has been instrumental in
advancing the field of immunotherapy. Despite the prominence of these treatments, many …

The development of immunotherapies over the past decade has resulted in a paradigm shift
in the treatment of cancer. However, the majority of patients do not benefit from …

There has been significant progress in utilizing our immune system against cancer, mainly
by checkpoint blockade and T cell-mediated therapies. The field of cancer immunotherapy is …

Novel therapies targeting immune checkpoint molecules have redefined the treatment of
cancer at advanced stages and brought hope to millions of patients worldwide. Monoclonal …